STS

Mass Megawatts Announces Several New Product Lines with Lowest and Competitive Prices as a Source of Generating Revenue

Retrieved on: 
Thursday, February 22, 2024

We sell and supply the top brands when it comes to solar equipment from solar panels, racking, inverters, wiring, and more.

Key Points: 
  • We sell and supply the top brands when it comes to solar equipment from solar panels, racking, inverters, wiring, and more.
  • We can also supply equipment for both generating and storing your own power at the best prices available.
  • Our products are sourced from top manufacturers, ensuring that you receive reliable and long-lasting equipment for your solar energy needs.
  • Unlike other solar tracking technologies, the Mass Megawatts Solar Tracker utilizes a low-cost framework that adds stability to the overall system, while improving energy production levels.

Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients with first-line advanced or metastatic Soft Tissue Sarcoma

Retrieved on: 
Tuesday, February 20, 2024

SIENA, Italy, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Philogen S.p.A. (BIT:PHIL) is pleased to announce that the Phase III FIBROSARC trial (NCT04650984) will continue as planned by the protocol. The decision was made by an Independent Data and Safety Monitoring Board (DSMB) following the review of efficacy and safety data in the pre-planned interim analysis.

Key Points: 
  • The decision was made by an Independent Data and Safety Monitoring Board (DSMB) following the review of efficacy and safety data in the pre-planned interim analysis.
  • FIBROSARC is a Phase III 1:1 randomized trial (NCT04650984) which studies L19TNF in combination with doxorubicin (Experimental Arm) versus doxorubicin alone (Control Arm) in 118 patients as first-line therapy for advanced or metastatic Soft Tissue Sarcoma (STS).
  • The Phase III FIBROSARC trial was designed to demonstrate a significant clinical benefit of L19TNF plus doxorubicin compared to doxorubicin alone.
  • For more information about Onfekafusp alfa (also known as Fibromun), FIBROSARC Phase III study (NCT04650984), Soft Tissue Sarcoma, and Philogen, please visit https://www.philogen.com/investors/press-releases/ .

KBR to Hold Sustainable Technology Solutions Primer Webinar

Retrieved on: 
Tuesday, February 27, 2024

HOUSTON, Feb. 27, 2024 /PRNewswire/ -- KBR (NYSE: KBR) announced today that it will hold a webcast of their Sustainable Technology Solutions (STS) Primer on Tuesday, March 12, 2024, beginning at 8:00 a.m. Central Time (9:00 a.m. Eastern Time).

Key Points: 

HOUSTON, Feb. 27, 2024 /PRNewswire/ -- KBR (NYSE: KBR) announced today that it will hold a webcast of their Sustainable Technology Solutions (STS) Primer on Tuesday, March 12, 2024, beginning at 8:00 a.m. Central Time (9:00 a.m. Eastern Time).

Kratos Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 13, 2024

Adjusted earnings per share (EPS) was $0.12 for the fourth quarter of 2023, compared to $0.08 for the fourth quarter of 2022.

Key Points: 
  • Adjusted earnings per share (EPS) was $0.12 for the fourth quarter of 2023, compared to $0.08 for the fourth quarter of 2022.
  • Fourth quarter 2023 Revenues of $273.8 million increased $24.5 million, reflecting 9.8 percent and 7.3 percent organic growth, respectively, from fourth quarter 2022 Revenues of $249.3 million.
  • KUS’s Operating Income was $1.0 million in the fourth quarter of 2023 compared to $1.8 million in the fourth quarter of 2022.
  • KUS’s Adjusted EBITDA for the fourth quarter of 2023 was $4.0 million, compared to fourth quarter 2022 KUS Adjusted EBITDA of $4.5 million, reflecting reduced volume.

RRD President and CEO Thomas J. Quinlan III to be Honored at the Third Annual Soldiers to Sidelines Legacy of Leadership Dinner

Retrieved on: 
Wednesday, February 7, 2024

Donnelley & Sons Company ( RRD ), a leading global provider of marketing, packaging, print, and supply chain solutions, today announced that Thomas J. Quinlan III, President and Chief Executive Officer of RRD, will be an honoree at the 2024 Soldiers to Sidelines Legacy of Leadership Dinner.

Key Points: 
  • Donnelley & Sons Company ( RRD ), a leading global provider of marketing, packaging, print, and supply chain solutions, today announced that Thomas J. Quinlan III, President and Chief Executive Officer of RRD, will be an honoree at the 2024 Soldiers to Sidelines Legacy of Leadership Dinner.
  • In its third year, the Legacy of Leadership Dinner by Soldiers To Sidelines (STS) – a non-profit veteran service organization – honors three influential leaders each year for their legacy in coaching, the military, and business.
  • “I am incredibly humbled to be an honoree at the third annual STS Legacy of Leadership Dinner.
  • The 2024 Legacy of Leadership Dinner will be held at the Ritz-Carlton in Washington, DC on Monday, February 26, 2024.

Thermosome Announces Further Dose Escalation in Phase I Trial with Lead Program THE001

Retrieved on: 
Tuesday, February 6, 2024

Munich, Germany – February 6, 2024 – Thermosome , a drug development company specializing in targeted tumor therapies, today announced that it received clearance by the independent Data Safety Monitoring Board (DSMB) to proceed as planned with the dose escalation in its ongoing Phase I trial of its lead program THE001.

Key Points: 
  • Munich, Germany – February 6, 2024 – Thermosome , a drug development company specializing in targeted tumor therapies, today announced that it received clearance by the independent Data Safety Monitoring Board (DSMB) to proceed as planned with the dose escalation in its ongoing Phase I trial of its lead program THE001.
  • The first dose level was 20mg/m2, the second, recently initiated dose level is 40mg/m2.
  • Primary endpoints of the study are the safety and tolerability of THE001 and the determination of the maximum tolerated dose.
  • "The independent Data Safety Monitoring Board has assessed that our lead candidate is safe and well tolerated at the first dose level.

FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin

Retrieved on: 
Thursday, February 1, 2024

PEDMARK is the first and only FDA approved therapy indicated to reduce the risk of ototoxicity (e.g., permanent hearing loss) associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors.

Key Points: 
  • PEDMARK is the first and only FDA approved therapy indicated to reduce the risk of ototoxicity (e.g., permanent hearing loss) associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors.
  • The FDA reminded health care providers that as stated in PEDMARK’s prescribing information , PEDMARK is not substitutable with other sodium thiosulfate products.
  • Sodium nitrite is co-packaged with sodium thiosulfate as a separate vial in some products; it is not present in PEDMARK.
  • The FDA encourages those with any questions to contact [email protected].

California Dreaming: Escape Las Vegas' Big Game Crowds with Super-Low Fares to L.A. and California Wine Country

Retrieved on: 
Wednesday, January 31, 2024

LAS VEGAS, Jan. 31, 2024 /PRNewswire/ -- For Vegas residents looking to escape the crowds of the Big Game, Avelo Airlines announced today it is adding special nonstop roundtrip flights from Las Vegas to L.A. and California Wine Country.

Key Points: 
  • One-way fares from Vegas to L.A. and Sonoma County start at $51
    LAS VEGAS, Jan. 31, 2024 /PRNewswire/ -- For Vegas residents looking to escape the crowds of the Big Game, Avelo Airlines announced today it is adding special nonstop roundtrip flights from Las Vegas to L.A. and California Wine Country.
  • During the Big Game weekend (Friday February 9 through Monday February 12) Avelo is adding flights from Las Vegas' Harry Reid International Airport (LAS) to L.A.'s most convenient and popular airport – Hollywood Burbank Airport (BUR) – and California Wine Country's Charles M. Schulz-Sonoma County Airport (STS).
  • Avelo Airlines Chairman and CEO Andrew Levy said, "These special flights will make it easy for people to escape the congestion that accompanies the Big Game.
  • What better way to spend a long weekend away from the Vegas crowds than soaking in the Southern California sun or sampling some Northern California wines."

Avelo Airlines Cheering On 49ers with Special Super Bowl Flights from Bay Area's Sonoma Airport to Vegas

Retrieved on: 
Tuesday, January 30, 2024

SAN FRANCISCO and SANTA ROSA, Calif., Jan. 29, 2024 /PRNewswire/ -- Avelo Airlines announced today it is adding special nonstop roundtrip flights between the Bay Area's Charles M. Schulz-Sonoma County Airport (STS) and Las Vegas' Harry Reid International Airport (LAS) for Super Bowl LVIII.

Key Points: 
  • SAN FRANCISCO and SANTA ROSA, Calif., Jan. 29, 2024 /PRNewswire/ -- Avelo Airlines announced today it is adding special nonstop roundtrip flights between the Bay Area's Charles M. Schulz-Sonoma County Airport (STS) and Las Vegas' Harry Reid International Airport (LAS) for Super Bowl LVIII.
  • We look forward to joining our fellow Bay Area fans in cheering on the Niners in Super Bowl LVIII."
  • Every Avelo flight is nonstop and on almost every route at least one airport on every Avelo flight is a small, easy to use airport.
  • Unlike most other airlines, Avelo Customers can always change or cancel their itineraries with no extra fees.

Nevada Canyon Announces Appointment of New Directors

Retrieved on: 
Thursday, January 18, 2024

Reno, Nevada, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Nevada Canyon Gold Corp. (OTC Markets: NGLD) (the “Company” or “Nevada Canyon”) is pleased to announce the appointment of Mr. John Schaff, B.Sc.

Key Points: 
  • Reno, Nevada, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Nevada Canyon Gold Corp. (OTC Markets: NGLD) (the “Company” or “Nevada Canyon”) is pleased to announce the appointment of Mr. John Schaff, B.Sc.
  • as new independent directors to its Board of Directors, effective immediately.
  • With the appointment of these additional Directors, the Board is now comprised of five (5) directors, of which three (3) are considered independent.
  • “We’re excited to expand our board of directors with these new members who bring both a wealth of experience in Nevada and contacts to the Company,” said Jeffrey Cocks, Chairman of the Board of Directors of the Company.